Search

OBJECTIVE: To evaluate whether the Pretransplantion Assesment of Mortality risk score is associated to transplant costs and can be used not only to predict mortality but also as a cost management tool. METHODS: We evaluated consecutively patients submitted to allogeneic (n = 27) and autologous (n = 89) hematopoietic stem cell-transplantation from 2004 to 2006 at Hospital Israelita Albert Einstein (SP), Brazil. Participants mean age at hematopoietic stem cell-transplantation was 42 (range 1 to 72) years; there were 69 males and 47 females; 30 patients had multiple myeloma; 41 had non-Hodgkin and Hodgkin's lymphomas; 22 had acute leukemia; 6 had chronic leukemia; and 17 had non-malignant disease. The Pretransplantion Assesment of Mortality risk score was applied in all patients using the available web site. RESULTS: Patients could be classified in three risk categories: high, intermediate and low, having significant difference in survival (p = 0.0162). The median cost in US dollars for each group was $ 281.000, $ 73.300 and $ 54.400 for high, intermediate and low risk, respectively. The cost of hematopoietic stem cell-transplantation significantly differed for each Pretransplantin Assesment of Mortality risk group (p = 0.008). CONCLUSION: The validation of the Pretransplantion Assesment of Mortality risk score in our patients confirmed that this system is an important tool to be used in transplantation units, being easy to apply and fully reproducible.

Objective: To evaluate whether the Pretransplantion Assesment ofMortality risk score is associated to transplant costs and can beused not only to predict mortality but also as a cost managementtool. Methods: We evaluated consecutively patients submitted toallogeneic (n = 27) and autologous (n = 89) hematopoietic stemcell-transplantation from 2004 to 2006 at Hospital Israelita AlbertEinstein (SP), Brazil. Participants mean age at hematopoietic stemcell-transplantation was 42 (range 1 to 72) years; there were 69males and 47 females; 30 patients had multiple myeloma; 41 hadnon-Hodgkin and Hodgkin’s lymphomas; 22 had acute leukemia;6 had chronic leukemia; and 17 had non-malignant disease. ThePretransplantion Assesment of Mortality risk score was applied inall patients using the available web site (http://cdsweb.fhcrc.org/pam/). Results: Patients could be classified in three risk categories:high, intermediate and low, having significant difference in survival(p = 0.0162). The median cost in US dollars for each group was$ 281.000, $ 73.300 and $ 54.400 for high, intermediate and low risk,respectively. The cost of hematopoietic stem cell-transplantationsignificantly differed for each Pretransplantin Assesment ofMortality risk group (p = 0.008). Conclusion: The validation of thePretransplantion Assesment of Mortality risk score in our patientsconfirmed that this system is an important tool to be used intransplantation units, being easy to apply and fully reproducible.